Clinical Trial Update: Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer [Phase 1]

View source ↗

Summary

This open-label Phase 1 trial investigates the duration of severe neutropenia after same-day dosing of eflapegrastim in breast cancer patients; the study is com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• eflapegrastim (eflapegrastim)

Snippet

Sponsor: Spectrum Pharmaceuticals, Inc | Conditions: Neutropenia, Breast Cancer | Phase 1 | Status: COMPLETED